{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:31:26Z","timestamp":1785148286753,"version":"3.55.0"},"reference-count":21,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.25027","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T22:07:54Z","timestamp":1751062074000},"page":"146-152","source":"Crossref","is-referenced-by-count":1,"title":["Pemigatinib therapy in myeloid\/lymphoid neoplasm with FGFR1 rearrangement manifesting as aggressive B-cell lymphoma"],"prefix":"10.3960","volume":"65","author":[{"given":"Kenichi","family":"Ito","sequence":"first","affiliation":[{"name":"Hematology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Hirano","sequence":"additional","affiliation":[{"name":"Laboratory and Pathology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"Hematology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan,"},{"name":"Clinical Research Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Loghavi S, Cross NCP, Haferlach C, Padron E, Patnaik M. Myeloid\/lymphoid neoplasm with FGFR1 rearrangement. In: The WHO Classification of Tumours Editorial Board, Eds. World Health Organization classification of tumours. 5th ed. Haematolymphoid tumours. Lyon, IARC Press. 2024; pp.191-193."},{"key":"2","unstructured":"2 Macdonald D, Aguiar RC, Mason PJ, Goldman JM, Cross NC. A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia. 1995; 9: 1628-1630."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol. 2010; 41: 461-476.","DOI":"10.1016\/j.humpath.2009.11.003"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Smedley D, Demiroglu A, Abdul-Rauf M <i>et al.<\/i> ZNF198-FGFR1 transforms Ba\/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5. Neoplasia. 1999; 1: 349-355.","DOI":"10.1038\/sj.neo.7900035"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Patnaik MM, Gangat N, Knudson RA <i>et al.<\/i> Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. Am J Hematol. 2010; 85: 238-242.","DOI":"10.1002\/ajh.21631"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Vega F, Medeiros LJ, Bueso-Ramos CE, Arboleda P, Miranda RN. Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. Am J Clin Pathol. 2015; 144: 377-392.","DOI":"10.1309\/AJCPMORR5Z2IKCEM"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Strati P, Tang G, Duose DY <i>et al.<\/i> Myeloid\/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 2018; 59: 1672-1676.","DOI":"10.1080\/10428194.2017.1397663"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Umino K, Fujiwara SI, Ikeda T <i>et al.<\/i> Clinical outcomes of myeloid\/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement. Hematology. 2018; 23: 470-477.","DOI":"10.1080\/10245332.2018.1446279"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Chen J, Deangelo DJ, Kutok JL <i>et al.<\/i> PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA. 2004; 101: 14479-14484.","DOI":"10.1073\/pnas.0404438101"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Chase A, Bryant C, Score J, Cross NC. Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica. 2013; 98: 103-106.","DOI":"10.3324\/haematol.2012.066407"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Vannucchi AM, Patel JL, Shomali WE <i>et al.<\/i> MPN-384 A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients With Myeloid\/Lymphoid Neoplasms With Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Rearrangement. Clin Lymphoma Myeloma Leuk. 2024; 24: S430-S431.","DOI":"10.1016\/S2152-2650(24)01430-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018; 131: 2761-2772.","DOI":"10.1182\/blood-2018-01-791376"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Cheson BD, Ansell S, Schwartz L <i>et al.<\/i> Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016; 128: 2489-2496.","DOI":"10.1182\/blood-2016-05-718528"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Byrd JC, Hillmen P, Ghia P <i>et al.<\/i> Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol. 2021; 39: 3441-3452.","DOI":"10.1200\/JCO.21.01210"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Metzgeroth G, Steiner L, Naumann N <i>et al.<\/i> Myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort. Leukemia. 2023; 37: 1860-1867.","DOI":"10.1038\/s41375-023-01958-1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Valent P, Klion AD, Horny HP <i>et al.<\/i> Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012; 130: 607-612.e9.","DOI":"10.1016\/j.jaci.2012.02.019"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017; 129: 704-714.","DOI":"10.1182\/blood-2016-10-695973"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022; 97: 129-148.","DOI":"10.1002\/ajh.26352"},{"key":"19","unstructured":"19 Vannucchi AM, Patel JL, Shomali WE, <i>et al.<\/i> A phase 2 study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid\/lymphoid neoplasms with fibroblast growth factor receptor 1 gene rearrangement [poster]. Presented at: European Hematology Association Hybrid Congress; 2024 Jun 13\u201316; Madrid, Spain."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016; 17: 779-790.","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Zenz T, Kreuz M, Fuge M <i>et al.<\/i> TP53 mutation and survival in aggressive B cell lymphoma. Int J Cancer. 2017; 141: 1381-1388.","DOI":"10.1002\/ijc.30838"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/2\/65_25027\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T04:45:31Z","timestamp":1751085931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/2\/65_25027\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25027","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25027"}}